Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 08/11/22
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ETGlobeNewsWire • 08/04/22
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)GlobeNewsWire • 07/05/22
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b TrialGlobeNewsWire • 06/10/22
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, AustriaGlobeNewsWire • 05/12/22
Fulcrum Therapeutics, Inc. (FULC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 05/09/22
Fulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial ResultsGlobeNewsWire • 05/09/22
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare ConferenceGlobeNewsWire • 05/05/22
After Plunging 59.2% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics, Inc. (FULC)Zacks Investment Research • 05/03/22
Earnings Preview: Fulcrum Therapeutics, Inc. (FULC) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/22
Is the Options Market Predicting a Spike in Fulcrum (FULC) Stock?Zacks Investment Research • 04/04/22
Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?Zacks Investment Research • 04/01/22
Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology's Annual MeetingGlobeNewsWire • 04/01/22
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)GlobeNewsWire • 03/17/22
Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific ConferenceGlobeNewsWire • 03/14/22
Does Fulcrum Therapeutics, Inc. (FULC) Have the Potential to Rally 179% as Wall Street Analysts Expect?Zacks Investment Research • 03/07/22
Fulcrum Therapeutics, Inc.'s (FULC) CEO Bryan Stuart On Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/03/22
Fulcrum Therapeutics Latest Report On Its Sickle Cell Disease TrialsThe Dog of Wall Street • 01/08/22
Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease TreatmentBenzinga • 12/06/21
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call TranscriptSeeking Alpha • 11/06/21